SOURCE: Emergent Health Corp

April 29, 2008 12:40 ET

Emergent Health Corp. (EMGN) Announces New Initiatives to Increase Market Presence

MYRTLE BEACH, SC--(Marketwire - April 29, 2008) - Emergent Health Corp. (PINKSHEETS: EMGN) announces several new initiatives. Emergent has issued a Letter of Interest to acquire a long established distributor to dispensing physicians. This could bring an up to $1,000,000 in sales launch pad for Emergent. Secondly, discussions are also underway for a potential research grant funding for a $500,000 R&D program. This could expand Emergent's research position in the field of stem cell research without the outlay of corporate funds. Point of sales display beta testing for products have been successful and Emergent is currently seeking distributors to expand placement of these displays.

Emergent is also currently beta testing three websites, Corporate ( as well as product test site for Hungarest™ Diet Aid ( and Vita-Stim™ Life Enhancement (

Emergent engages in the discovery, development and marketing of products designed to better mankind. Emergent believes it is positioning itself as a leader in the field of Regenerative Medicine defined by the National Institute of Health using nutritionally designed products. Intended products are to be marketed under third-party label exemptions. Emergent is focusing current efforts on marketing licensed patent pending natural stem cell mobilizing agents capable of enhancing each individual's ability to increase their own adult stem cells from their bone marrow. Emergent is also licensed under a patent pending application to market a dual acting all natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and Professional markets. Research and Development is exploring other areas such as Secretogues that can naturally enhance a person's own Growth Hormone production and similar all natural bioactive formulations to enhance human performance safely, ethically, legally and utilizing known body mechanisms without the use of drugs. Emergent does not claim any of its products diagnose, treat, cure or prevent any disease. Emergent was founded in 2006 and headquartered in Myrtle Beach, SC.

This press release contains certain "forward-looking" statements, as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the company.

This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.

Contact Information

  • For Investor Relations:
    Investor Development Group, LLC
    Robert Adams